In this article, we will take a detailed look at 10 stocks with at least $10 million in insider sales recently. We previously covered 10 stocks with at least $30 million in insider spending recently.
Some of the major U.S. indexes began recovering on Wednesday, following the Trump administration’s announcement of a one-month delay on tariffs for automakers meeting the United States-Mexico-Canada Agreement (USMCA) requirements. The news sparked enthusiasm among traders, who began hoping for additional exemptions, causing the major stock indexes to rise slightly.
Blue-chip companies gained 485.60 points or 1.14%, the broader market index rose 1.12%, while the NASDAQ stocks increased 1.46%. These rebounds come during a volatile week following a period of consecutive declines.
Although many analysts have lowered their U.S. stock forecasts, citing that strong earnings in 2025 may be more challenging to achieve, the broader market index is still projected to end the year about 9% higher than in 2024. However, this is lower than the initial forecast of 12.2%, made in early January.
On the other hand, the big bets for this year are a productivity boost from the adoption of AI and the projection of lower interest rates. Dan Ives, global head of technology research at Wedbush Securities, said that while tariffs are never good for Wall Street, investors should take advantage of these periods to invest in the best tech stocks, reports CNN Business.
Amid market fluctuations and uncertainty, insider trading often attracts significant attention. Executives and insiders, with their in-depth knowledge of company strategies, plans, and future prospects, may make trades worth analyzing. For instance, when a CEO or CFO invests their own funds in company stock, it can serve as a strong indicator of confidence in the company’s future potential.
Selling shares, on the other hand, may suggest that management is losing confidence, though this is not always the case. In some instances, large shareholders may simply be rebalancing their portfolios to better align with their desired risk/reward profile or selling for personal financial reasons. Additionally, many insiders sell shares as part of pre-arranged, automated trading plans known as 10b5-1 plans.
Both insider buying and selling can be influenced by various factors, so these actions should be interpreted within the broader context of the company’s financial health, industry trends, and overall market conditions. This highlights the importance of conducting thorough research before making investment decisions. While insider trading activity can offer valuable insights into a company’s prospects, it should be considered alongside other critical factors to ensure well-informed investment choices.
A close up of a financial trader typing on a laptop at a market trading desk.
Today, we’re focusing on stocks that have seen insider sales of at least $10 million since the start of the year. Using Insider Monkey’s insider trading screener, we identified stocks where at least one insider sale reached $10 million or more. While the total value of insider sales for these stocks may be higher, we focused on sales worth $10 million or more. Out of the stocks that met this criterion, we selected the 10 stocks with insider sales ranging from $10 million to $20 million, prioritizing those with the highest insider sales within this range for further analysis.
Our research has shown that we can outperform the market by imitating the top stock picks of the best hedge funds, focusing on insider trading and stock picks from hedge fund investor newsletters and conferences. Our quarterly newsletter’s strategy selects 14 small-cap and large-cap stocks every quarter and has returned 373.4% since May 2014, beating its benchmark by 218 percentage points (see more details here).
For each stock, we provide details on the highest individual sale, the number of insider sales exceeding $10 million year-to-date, and the company’s current market capitalization. Let’s take a look at 10 stocks with at least $10 million in insider sales since the beginning of the year.
10. AbbVie Inc. (NYSE:ABBV)
Highest Individual Sale: $18,964,470.60
Number of Sales Above $10 million: 1
Market Capitalization: $373.44 billion
AbbVie is a biopharmaceutical company engaged in the development of advanced therapies across various healthcare sectors. The North Chicago, Illinois-headquartered company offers a broad range of treatments in immunology, oncology, neurology, and eye care. It also markets well-known cosmetic products such as Juvederm and Botox for skincare and anti-aging.
On February 28, one insider sold $18.96 million worth of AbbVie shares at a price of $205.11 per share. AbbVie shares jumped that day on the news that The European Medicines Agency’s CHMP has recommended approving upadacitinib for treating adults with giant cell arteritis (GCA). The final decision from the European Commission is expected by mid-2025. If approved, upadacitinib would be the first oral advanced therapy for adults with GCA.
Currently, the stock is trading at $211.54 per share, having risen 19.04% since the beginning of the year. Over the past 12 months, AbbVie returned 16.83% to its investors.
In March, AbbVie and Gubra A/S (CPSE:GUBRA), announced a licensing agreement to develop GUB014295, a potential long-acting amylin analog for obesity treatment. GUB014295, currently in Phase 1 trials, is designed to activate amylin and calcitonin receptors, with amylin identified as a key target for obesity treatment. AbbVie views this partnership as an opportunity to enter the obesity field and drive long-term growth.
Twenty-one analysts have given an average “Strong Buy” rating to AbbVie stock, with a price target of $212.7, according to Stock Analysis.
AbbVie is also one of the 10 most undervalued long term stocks to buy now.
9. Amkor Technology, Inc. (NASDAQ:AMKR)
Highest Individual Sale: $18,999,995.25
Number of Sales Above $10 million: 2
Market Capitalization: $5.11 billion
Ninth stock among the 10 with at least $10 million in insider sales this year, is a provider of outsourced semiconductor packaging and testing services across the U.S., Japan, Europe, and the Asia Pacific region, Amkor Technology. The Tempe, Arizona-based company provides turnkey packaging and testing services, such as semiconductor wafer bump, wafer probe, wafer back-grind, package design, packaging, system-level and final testing, and more. It is also one of the 10 stocks with at least $10 million in insider spending recently.
On February 24, one insider made two sales each valued at nearly $19 million. J James Kim, who is a large shareholder at Amkor sold a total of 1.74 million shares at a price of $21.85 per share. Currently, the stock is trading at $20.72 per share, having lost 19.35% year-to-date.
In February, the company’s board of directors declared a quarterly cash dividend of $0.08269 per share on the company’s common stock.
For the full year of 2024, Amkor disclosed net sales of $6.32 billion, down from $6.50 billion in 2023. Net income attributable to Amkor was $354 million, or $1.43 per diluted share, compared to $360 million, or $1.46 per diluted share, in 2023.
Ten analysts have an average “Moderate Buy” rating on Amkor stock, with a price target of $31.50, according to MarketBeat. The average price target represents an upside of 52.03% from the current price.
8. Tempus AI, Inc. (NASDAQ:TEM)
Highest Individual Sale: $19,293,002.93
Number of Sales Above $10 million: 6
Market Capitalization: $9.14 billion
Tempus AI is a health technology company focused on integrating artificial intelligence and machine learning to advance precision medicine. The Chicago, Illinois-based company boasts one of the world’s largest libraries of clinical and molecular data, supported by an operating system designed to make this data both accessible and actionable.
In February, Tempus AI completed its acquisition of Ambry Genetics, a leading player in genetic testing aimed at improving health through a deeper understanding of the connection between genetics and disease. The deal was valued at $375 million in cash and $225 million in stock, with $100 million of the stock subject to a lock-up agreement for one year after the transaction’s close.
For 2024, Tempus AI reported revenue of $693 million, reflecting a year-over-year growth of approximately 30%. In the fourth quarter, its revenue grew 35.7% to $200.7 million. The company attributed this strong revenue growth to market adoption of both genomic testing and data services. In the quarter, Tempus AI also delivered a 49.7% increase in gross profit.
Tempus AI went public in June 2024, and since then it returned 31.83% to its investors. It is also considered one of Wall Street’s top 10 AI stocks to watch right now.
Twelve analysts have an average “Moderate Buy” rating on Tempus AI stock, with a price target of $59.73, according to MarketBeat.
7. Palo Alto Networks, Inc. (NASDAQ:PANW)
Highest Individual Sale: $19,396,036.65
Number of Sales Above $10 million: 16
Market Capitalization: $122.01 billion
Seventh among the 10 stocks with at least $10 million in insider sales recently is a global provider of cybersecurity solutions, Palo Alto Networks. The Santa Clara, California-based company offers a range of network security platforms, including Prisma Access, a security services edge (SSE) solution, and Strata Cloud Manager, a network security management tool. Additionally, Palo Alto Networks provides cloud security solutions such as Prisma Cloud, a cloud-native application protection platform, and the Code to Cloud platform. The company also offers VM-Series and CN-Series virtual firewalls for inline network security in multi-cloud and hybrid-cloud environments.
This week, the company launched Prisma SASE 5G, providing the tools needed to ensure protection in the future of mobility and connectivity. The company also announced the expansion of its private 5G partnerships, collaborating with seven industry leaders to offer comprehensive private 5G security solutions for enterprise deployments.
Since the beginning of the year, the company’s CEO, Nikesh Arora, made 16 sales of his Palo Alto Networks shares. Out of these transactions, one was worth $19.4 million, when Arora sold 106,747 shares at a price of $181.70 per share. Currently, the stock is trading at $184.28 per share, having gained 1.28% since the beginning of the year. Over the past 12 months, Palo Alto Networks returned 32.17% to its investors.
Mad Money host, Jim Cramer recently commented on the stock saying, “Nikesh Arora put up a really good quarter. The headlines were out immediately. Before they even could read the release, sellers came in. Had they read the release, they would’ve realized it is fine. I like Palo Alto very much. It’s a great way to get involved in cybersecurity.”
Cramer added Arora created $104 billion in value for the company.
MarketBeat reveals that 42 analysts have an average “Moderate Buy” on Palo Alto Networks stock, with a price target of $205.6.
6. Dell Technologies Inc. (NYSE:DELL)
Highest Individual Sale: $19,442,545.56
Number of Sales Above $10 million: 10
Market Capitalization: $67.85 billion
Dell Technologies is a leading multinational technology company giant. The Round Rock, Texas-based company provides a broad range of computing, storage, networking, cybersecurity, and IT solutions. It designs, develops, manufactures, and sells products such as personal computers, servers, data storage devices, network switches, software, and peripherals, with a focus on delivering comprehensive IT infrastructure solutions for both businesses and consumers globally.
In January, one insider made 10 sales of Dell shares, out of which two were worth $19.4 million each. During these transactions, the insider sold a total of 324,936 shares at a price of $119.67 per share. Currently, the stock is trading at $97.25 per share, having declined 15.61% year-to-date.
For the full year of 2024, the company reported revenue of $95.6 billion, up 8% year-over-year and operating income of $6.2 billion, up 15% from 2023. It also disclosed record full-year diluted earnings per share of $6.38, up 39% year-over-year. Dell’s board of directors declared a cash dividend increase of 18%.
The company provided fiscal year 2026 guidance with full-year revenue growth of 8%, diluted EPS growth of 23% and non-GAAP diluted EPS growth of 14%.
Seventeen analysts have given an average “Strong Buy” rating to Dell stock, with a price target of $143.29, according to StockAnalysis.
Dell is also one of the 10 cheap technology stocks to buy according to hedge funds.
5. Eli Lilly and Company (NYSE:LLY)
Highest Individual Sale: $19,507,205.25
Number of Sales Above $10 million: 24
Market Capitalization: $835.05 billion
In the middle of this list of 10 stocks with $10 million in insider sales recently is a multinational pharmaceutical firm, Eli Lilly and Company. Commonly known as Lilly, the Indianapolis, Indiana-headquartered company has offices in 18 countries and its products have reached approximately 125 countries worldwide. It is also one of the top 10 stocks to buy according to Lone Pine Capital.
Lilly is known for its clinical depression drugs Prozac (1986), Cymbalta (2004), and its antipsychotic medication Zyprexa (1996). Its primary revenue drivers are the diabetes drugs Humalog (1996) and Trulicity (2014).
Since the beginning of the year, one insider made 24 sales of Eli Lilly shares. One of the transactions was worth $19.51 million, during which the insider sold 21,025 shares at a price of $927.81 per share. Currently, the stock is trading at $929.72, having gained 20.43% year-to-date.
Recently, Lilly announced it plans to bolster its domestic medicine production across therapeutic areas by building four new pharmaceutical manufacturing sites in the U.S. This brings the company’s total capital expansion commitments to more than $50 billion since 2020.
Last week, the company also confirmed that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion for Jaypirca (pirtobrutinib), a reversible Bruton’s tyrosine kinase (BTK) inhibitor. The treatment is recommended for adult patients with relapsed or refractory chronic lymphocytic leukemia (CLL) who have previously been treated with a BTK inhibitor. The news caused its shares to jump 2.713%, from $905.16 to $929.72 per share.
Twenty analysts have an average “Moderate Buy” rating on Lilly stock, with a price target of $1,007.50 per share, according to MarketBeat.
4. Doximity, Inc. (NYSE:DOCS)
Highest Individual Sale: $19,511,407.26
Number of Sales Above $10 million: 3
Market Capitalization: $13.04 billion
Doximity operates an online platform tailored for medical professionals in the U.S. The San Francisco, California-based company offers a cloud-based software that allows physicians and healthcare professionals to collaborate with their colleagues, conduct virtual patient visits, coordinate patient care, manage their careers, and stay on top of the latest medical developments.
Recently, the company announced that Doximity Dialer has been named 2025 Best in KLAS in the Video Conferencing Platforms segment. This was the fourth consecutive year that Doximity has earned the top position.
In February, the company’s CEO, Jeffrey Tangney, made three sales, out of which one was valued at $19.51 million. At that time, Tangney sold 260,624 shares at a price of $74.86 per share. Currently, the stock is trading at $69.51 per share, having gained 30.19% year-to-date. Over the past 12 months, Doximity returned 147.28% to its investors.
Doximity reported a 57% year-over-year increase in net income for the third quarter of fiscal year 2024, reaching $75.2 million. Revenue also saw a 24.6% year-over-year increase, amounting to $168.6 million. The company expects this growth to continue and projects full-year revenue for the fiscal year ending March 31, 2025, to range between $564.6 million and $565.6 million.
According to 18 Wall Street analysts, Doximity is a “Moderate Buy” with a price target of $72.50, writes TipRanks. The average price target represents a 4.30% upside from the current price.
Doximity is also one of the 10 best performing healthcare stocks so far in 2025.
3. Airbnb, Inc. (NASDAQ:ABNB)
Highest Individual Sale: $19,599,369.64
Number of Sales Above $10 million: 11
Market Capitalization: $88.59 billion
Third among 10 stocks with at least $10 million in insider sales recently is a world-popular online platform that allows hosts to offer accommodations and experiences to guests, Airbnb. The San Francisco, California-based company offers a marketplace that connects hosts and guests through its website and mobile app, enabling bookings for spaces and activities.
The company is continually enhancing its platform and plans to introduce over 500 new features and updates in the upcoming summer release. With a portfolio of 8 million listings and 5 million hosts, it is well-positioned for sustained growth.
On February 14, Airbnb’s CEO and chairman, Brian Chesky, made two sales, one valued at $19.6 million. That day, Chesky sold a total of 210,179 shares, at an average price of $160.93 per share. Currently, the stock is trading at $142.58, having risen 8.50% since the beginning of the year. Over the past 12 months, Airbnb lost 12.99%.
Airbnb is also one of the 12 companies Bezos is investing in.
Cramer recently praised the stock saying it is a company that keeps growing amid strong travel demand. “When you travel, you need someplace to stay, don’t you? They (Airbnb) just reported excellent numbers. These were cyclical stocks before COVID, but now they’re secular, meaning they seem to have growing growth no matter what.”
2. The Trade Desk, Inc. (NASDAQ:TTD)
Highest Individual Sale: $19,841,102.76
Number of Sales Above $10 million: 6
Market Capitalization: $33.01 billion
The Trade Desk is a technology company, which provides a self-service cloud-based ad-buying platform that enables users to manage and optimize data-driven digital advertising campaigns. The platform covers various formats, such as video, audio, digital-out-of-home, and social on multiple devices. Trade Desk is also one of the 10 tech stocks with high upside potential.
Since the beginning of the year, the company’s CEO and president, Terry Jeffrey Green, made six sales of the company’s shares in his ownership. One transaction was worth $19.84 million, during which Green sold 164,166 shares at a price of $120.86 per share. Currently, the stock is trading at $66.54, having declined 43.38% year-to-date.
For the full year of 2024, The Trade Desk reported revenue of $2.44 billion, up by 25.63% from 2023. Net income was $393.08 million, an increase of 119.67% year-over-year.
“The Trade Desk once again outpaced nearly every segment of digital advertising in 2024, delivering $2.4 billion of revenue – marking accelerated growth of 26% year over year – and a record $12 billion of spend on our platform,” stated Green. “At the same time, we achieved significant profitability and cash flow. While we are proud of these accomplishments, we are disappointed that we fell short of our own expectations in the fourth quarter.”
On February 12, when the company announced the results, the stock price dropped 32.97%.
Thirty-one analysts have an average “Buy” rating on the stock, with a price target of $118.39, according to StockAnalysis.
1. Universal Technical Institute, Inc. (NYSE:UTI)
Highest Individual Sale: $19,877,644.20
Number of Sales Above $10 million: 1
Market Capitalization: $1.5 billion
First among the 10 stocks with at least $10 million in insider sales recently is a provider of transportation, skilled trades and healthcare education programs in the U.S. The Orlando, Florida-based company operates in two segments — UTI and Concorde, offering certificate, diploma, or degree programs under various brands, such as Universal Technical Institute, Motorcycle Mechanics Institute, Marine Mechanics Institute, NASCAR Technical Institute, and MIAT College of Technology.
On February 10, one insider sold $19.88 million worth of Universal Technical Institute shares at a price of $28.20 per share. Currently, the stock is trading at $27.59, having gained 7.31% since the beginning of the year.
For the fiscal 2025 first quarter, the company reported revenue of $201.4 million, representing 15.3% growth versus the same period of fiscal 2024. Total new student starts grew 22.3% while average full-time active students grew 11.1% versus the comparable period in the prior year. Net income amounted to $22.2 million, an increase of 113.2% over the same period of fiscal 2024.
Six analysts have given a “Buy” rating to Universal Technical Institute stock with a price target of $31.17, according to MarketBeat.
Universal Technical Institute is also one of the 12 best education stocks to buy in 2025.
Overall, UTI ranks first among the 10 stocks with at least $10 million in insider sales recently. While we acknowledge the potential of UTI, our conviction lies in the belief that AI stocks hold greater promise for delivering higher returns, and doing so within a shorter time frame. If you are looking for an AI stock that is more promising than UTI but that trades at less than 5 times its earnings, check out our report about the cheapest AI stock.
READ NEXT: 20 Best AI Stocks To Buy Now and Complete List of 59 AI Companies Under $2 Billion in Market Cap
Disclosure: None. Insider Monkey focuses on uncovering the best investment ideas of hedge funds and insiders. Please subscribe to our free daily e-newsletter to get the latest investment ideas from hedge funds’ investor letters by entering your email address below.